Preferred Name |
busulfan |
|
Synonyms |
1,4-bis(methanesulfonoxy)butane |
|
Definitions |
A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties. Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA. Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C321" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C321" NCI Thesaurus) |
|
ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000041947 |
|
altLabel |
1,4-bis(methanesulfonoxy)butane Misulban WR-19508 Mylecytan busulphan glyzophrol Myeleukon Mitosan Bussulfam Mielucin Busulfanum BUS Myleran tetramethylene bis(methanesulfonate) 1,4-bitanediol dimethanesulfonate esters Sulfabutin 1,4-butanediol dimethylsulfonate BSF GT-41 1,4-di(methylsulfonyloxy)butane BU methanesulfonic acid, tetramethylene ester 1,4-di(methanesulfonyloxy)butane Busulfex Misulfan CB-2041 Myeloleukon Myelosan |
|
CAS Registry |
55-98-1 |
|
Component of |
http://purl.bioontology.org/ontology/PDQ/CDR0000041142 http://purl.bioontology.org/ontology/PDQ/CDR0000269827 http://purl.bioontology.org/ontology/PDQ/CDR0000041577 http://purl.bioontology.org/ontology/PDQ/CDR0000041918 http://purl.bioontology.org/ontology/PDQ/CDR0000392734 http://purl.bioontology.org/ontology/PDQ/CDR0000040146 http://purl.bioontology.org/ontology/PDQ/CDR0000041525 http://purl.bioontology.org/ontology/PDQ/CDR0000285704 http://purl.bioontology.org/ontology/PDQ/CDR0000042248 http://purl.bioontology.org/ontology/PDQ/CDR0000041820 http://purl.bioontology.org/ontology/PDQ/CDR0000043100 http://purl.bioontology.org/ontology/PDQ/CDR0000042321 http://purl.bioontology.org/ontology/PDQ/CDR0000041150 http://purl.bioontology.org/ontology/PDQ/CDR0000041923 http://purl.bioontology.org/ontology/PDQ/CDR0000041921 http://purl.bioontology.org/ontology/PDQ/CDR0000043101 http://purl.bioontology.org/ontology/PDQ/CDR0000042634 http://purl.bioontology.org/ontology/PDQ/CDR0000043054 http://purl.bioontology.org/ontology/PDQ/CDR0000043056 http://purl.bioontology.org/ontology/PDQ/CDR0000041860 http://purl.bioontology.org/ontology/PDQ/CDR0000042956 http://purl.bioontology.org/ontology/PDQ/CDR0000043304 http://purl.bioontology.org/ontology/PDQ/CDR0000041824 http://purl.bioontology.org/ontology/PDQ/CDR0000042060 http://purl.bioontology.org/ontology/PDQ/CDR0000041697 http://purl.bioontology.org/ontology/PDQ/CDR0000038500 http://purl.bioontology.org/ontology/PDQ/CDR0000041922 http://purl.bioontology.org/ontology/PDQ/CDR0000041621 |
|
cui |
C0728930 C0728928 C0939273 C0728926 C1511348 C0006463 C1522692 C1135149 C0728927 C1511349 C1522691 C0700015 C1522695 C0728924 |
|
Date last modified |
2014-02-20 |
|
definition |
A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties. Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA. Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C321" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C321" NCI Thesaurus) |
|
Legacy PDQ ID |
517 |
|
LT |
TRD |
|
NCI ID |
C321 |
|
notation |
CDR0000041947 |
|
NSC Code |
750 |
|
ORIG STY |
Drug/agent |
|
prefLabel |
busulfan |
|
tui |
T109 T131 T121 |